Roivant Sciences Ltd (ROIV) concluded trading on Thursday at a closing price of $11.38, with 5.22 million shares of worth about $59.45 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 1.97% during that period and on July 24, 2025 the price saw a loss of about -0.09%. Currently the company’s common shares owned by public are about 695.94M shares, out of which, 401.30M shares are available for trading.
Stock saw a price change of -2.32% in past 5 days and over the past one month there was a price change of -1.39%. Year-to-date (YTD), ROIV shares are showing a performance of 2.25% which decreased to -3.80% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $8.73 but also hit the highest price of $13.06 during that period. The average intraday trading volume for Roivant Sciences Ltd shares is 6.16 million. The stock is currently trading 0.58% above its 20-day simple moving average (SMA20), while that difference is up 1.68% for SMA50 and it goes to 1.80% higher than SMA200.
Roivant Sciences Ltd (NASDAQ: ROIV) currently have 695.94M outstanding shares and institutions hold larger chunk of about 65.73% of that.
The stock has a current market capitalization of $7.74B and its 3Y-monthly beta is at 1.15. It has posted earnings per share of -$0.25 in the same period. It has Quick Ratio of 33.47 while making debt-to-equity ratio of 0.02. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ROIV, volatility over the week remained 2.18% while standing at 2.52% over the month.
Stock’s fiscal year EPS is expected to drop by -393.55% while it is estimated to decrease by -8.50% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Goldman on July 10, 2025 offering a Buy rating for the stock and assigned a target price of $19 to it. Coverage by Wolfe Research stated Roivant Sciences Ltd (ROIV) stock as an Outperform in their note to investors on February 15, 2024, suggesting a price target of $17 for the stock. On January 05, 2024, Piper Sandler Initiated their recommendations, while on December 12, 2023, Deutsche Bank Initiated their ratings for the stock with a price target of $14. Stock get a Buy rating from Guggenheim on October 17, 2023.
